Welcome to our dedicated page for Haemonetics Corporation news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Corporation stock.
Haemonetics Corporation (NYSE: HAE) is a global leader in blood management solutions, dedicated to improving patient care and reducing healthcare costs. The company offers a comprehensive portfolio of integrated devices, information management systems, and consulting services that address every facet of blood and plasma management. Haemonetics operates through three key segments: Plasma, Blood Center, and Hospital.
In the Plasma segment, Haemonetics focuses on providing innovative technologies for plasma collection and processing. The company's products help ensure a steady supply of high-quality plasma for the production of biopharmaceuticals and other therapeutic applications.
Within the Blood Center segment, Haemonetics offers advanced solutions for blood component collection and processing, aiding in the optimization of blood supply chains. Despite facing high competition in this segment, the company continues to innovate and enhance its product offerings.
The Hospital segment is a significant growth area for Haemonetics, providing essential tools for surgical suites and transfusion services. The company's technologies help prevent unnecessary blood transfusions and ensure the right blood product is used at the right time, improving patient outcomes.
Recently, Haemonetics has achieved several milestones, including the acquisition of Attune Medical, the manufacturer of the FDA-cleared ensoETM® esophageal cooling device. This acquisition strengthens Haemonetics' presence in the electrophysiology market and complements its vascular closure offerings.
Haemonetics also received 510(k) clearance from the U.S. FDA for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge, expanding its capabilities to serve fully heparinized patients in critical surgical procedures.
The company's financial performance remains robust, with a strong focus on revenue growth and strategic investments. Haemonetics continues to explore new markets and develop cutting-edge technologies to stay at the forefront of the healthcare industry.
To stay updated with the latest developments and financial results, Haemonetics regularly hosts investor calls and webcasts, providing transparency and insights into its ongoing projects and future plans.
Haemonetics (NYSE: HAE) has announced the sale of its whole blood assets to GVS, S.p.A for up to $67.1M, including $44.6M upfront and potential earn-outs of $22.5M over four years. The deal includes Haemonetics' whole blood collection, processing and filtration solutions, along with manufacturing facilities in Covina, California and related assets in Tijuana, Mexico. The transaction is expected to close in Q1 2025.
Haemonetics will continue its Blood Center business, manufacturing apheresis solutions for automated blood collection. This move aligns with the company's strategy to focus on commercial and non-commercial plasma leadership and expand in high-growth hospital markets.
Haemonetics (NYSE: HAE) announced the availability of its second quarter fiscal year 2025 financial results, ended September 28, 2024, on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on November 7, 2024, at 8:00 a.m. ET to discuss the results. Participants are recommended to join 10 minutes before the event starts. A replay of the conference call and webcast will be available for one year starting November 7, 2024, at 11:00 a.m. ET.
Haemonetics (NYSE: HAE) has announced its plans to release second quarter fiscal year 2025 financial results on Thursday, November 7, 2024, at 6:00 am ET. The company will host a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results and answer questions. Interested parties can access the call via teleconference or through a live webcast on Haemonetics' investor relations website. Registration is required for the teleconference, and participants are advised to join 10 minutes before the event start. A replay of the conference call and webcast will be available for one year starting from November 7, 2024, at 11:00 am ET.
Haemonetics (NYSE: HAE) has announced the full market release of its VASCADE MVP® XL mid-bore venous closure system in the United States. This new addition to the VASCADE® portfolio features:
- 58% more collagen and a larger disc than the VASCADE MVP® system
- Designed for procedures requiring 10-12F sheaths (up to 15F in outer diameter)
- Suitable for cryoablation, Pulsed Field Ablation (PFA), and Left Atrial Appendage Closure (LAAC)
The system has been available in a market release since June 2024, used by approximately 80 physicians at over 30 hospitals. Haemonetics aims to expand indications for larger access points through ongoing clinical trials.
Haemonetics (NYSE: HAE) has announced the availability of its first quarter fiscal year 2025 financial results on its Investor Relations website. The company will host a conference call and webcast on August 8, 2024, at 8:00 a.m. ET to discuss the results with investors and analysts. Participants can access the call via a teleconference link or a live webcast. The earnings release referenced during the call is also available on the company's website. A replay of the conference call and webcast will be accessible for one year starting from August 8, 2024, at 11:00 a.m. ET.
Haemonetics (NYSE: HAE) has announced CE Mark certification and the first commercial European procedures for its SavvyWire® Pre-Shaped Pressure Guidewire. This innovative device is the world's first 3-in-1 solution for Transcatheter Aortic Valve Implantation (TAVI), offering improved procedural efficiency through predictable wire performance, hemodynamic measurement, and left-ventricular pacing capabilities.
The certification allows Haemonetics to enter EU markets and other regions recognizing CE marking. The first commercial European procedures were performed in France and The Netherlands. The SavvyWire guidewire reduces procedural device exchanges, provides stable aortic valve delivery, and enables continuous cardiac hemodynamic monitoring. It also allows for reliable LV pacing without additional devices or venous access.
Haemonetics (NYSE: HAE) announced it will publish its first quarter fiscal year 2025 financial results on August 8, 2024, at 6:00 am ET. The company has scheduled a conference call with investors and analysts at 8:00 am ET the same day to discuss the results and answer questions. Participants can access the call via teleconference upon registration, where they will receive a personalized PIN. It is recommended to join 10 minutes before the call starts. A live webcast will be available on Haemonetics' investor relations website, with a replay accessible for one year starting at 11:00 am ET on August 8, 2024.
Haemonetics (NYSE: HAE) has launched a market release of its new VASCADE MVP XL, a mid-bore venous closure device. This device is an extension of the VASCADE portfolio, featuring a collapsible disc and a resorbable collagen patch for rapid hemostasis. The VASCADE MVP XL system utilizes 58% more collagen and is designed for larger procedural sheaths up to 15F in outer diameter. It targets procedures like cryoablation and left atrial appendage closure for atrial fibrillation patients. The device has received pre-market approval from the FDA and the first procedure has been successfully performed by Dr. Tom McElderry at the University of Alabama at Birmingham. Haemonetics aims to capture a share of the $2.7 billion vascular closure market and plans a full market release later this year.
Haemonetics has announced the pricing of an upsized private placement of $600 million in 2.50% Convertible Senior Notes due 2029. The offering size increased from the previously announced $525 million. The notes are senior, unsecured obligations maturing on June 1, 2029, with a conversion price of $117.12 per share, a 30% premium over the last reported sale price. The net proceeds, estimated at $584.8 million, will be used to pay for capped call transactions, repurchase $200 million of 2026 notes, repay a $230 million revolving credit facility, and for other general purposes. Haemonetics has also granted an option to the initial purchasers to buy an additional $100 million in notes. The offering is expected to close on May 28, 2024.
On May 21, 2024, Haemonetics announced its plan to offer $525 million in Convertible Senior Notes due 2029 in a private offering to qualified institutional buyers.
An additional $75 million in notes may be offered if initial purchasers exercise their option. The notes will be senior, unsecured, and accrue interest semi-annually, to be settled in cash or common stock upon conversion.
Proceeds will fund capped call transactions to offset dilution and support general corporate purposes, potentially influencing the market price of Haemonetics' stock.
FAQ
What is the current stock price of Haemonetics Corporation (HAE)?
What is the market cap of Haemonetics Corporation (HAE)?
What does Haemonetics Corporation specialize in?
What are the main segments of Haemonetics' business?
What recent acquisitions has Haemonetics made?
What is the TEG® 6s hemostasis analyzer system?
How does Haemonetics support its plasma segment?
What are the financial highlights of Haemonetics?
How does Haemonetics improve patient care?
What was the significance of the FDA clearance for Haemonetics?
What is Haemonetics' approach to innovation?
How can investors stay updated on Haemonetics' performance?
